SMMT News and Press, Summit Therapeutics Inc. From 02/14/24

Financial Results & Operational Progress Call on February 20, 2024 Conference Call to be Held at 9:00am ET Summit Therapeutics Inc. (NASDAQ: SMMT) (“Summit,” “we,” or the “Company”) will host an earnings call to announce its fourth q...

Summit Therapeutics Inc. (NASDAQ: SMMT) (“Summit,” “we,” or the “Company”) today announced that it will participate in and present at Oppenheimer’s 34 th Annual Healthcare Life Sciences Conference, which will be held virtually. Summit will pres...

2024-01-30 07:16:26 ET Summary Summit's financial position is stable with adequate funds to support operations until H2 2024, despite a significant drop in cash reserves. Ivonescimab, SMMT's dual-acting compound targeting PD-1 and VEGF, shows promise in the field of oncology, part...

2024-01-22 12:04:50 ET Summary Acurx shares opened ~25% lower on Jan 17th, after releasing positive data suggesting its C. diff antibiotic outperformed standard treatment in restoring the gut microbiome. The decline in share price since then may be due to misaligned investor expec...

Phase II 24-Month OS Rate of 64.8% in 1L Squamous NSCLC Patients Phase II mOS of 22.5 Months in 2L+ EGFRm, TKI-progressed NSCLC Patients Catalyst Events Expected in Q2 2024 for Two Randomized Phase III Trials Evaluating Ivonescimab in China Conducted by Akeso, including Head-to-He...

Summit Therapeutics Inc. (NASDAQ: SMMT) (“Summit,” “we,” or the “Company”) today announced that it will participate in and present at the 42 nd Annual J.P. Morgan Healthcare Conference on Tuesday, January 09, 2024, at 1:30 PM PT. Robert W. Duggan, Cha...

2023-11-29 08:23:49 ET Losers: Seelos Therapeutics ( SEEL ) -43% on pricing of $5.55 million stock offering . Leslies ( LESL ) -20% after Q4 earnings release . Farfetch Ltd ( FTCH ) -16% . ESGL Holdings Ltd ( ESGL ) -15% . Petco ...

2023-11-07 14:56:04 ET Summit Therapeutics Inc. (SMMT) Q3 2023 Results Conference Call November 07, 2023 09:00 AM ET Company Participants Dave Gancarz - Chief Business and Strategy Officer Bob Duggan - Chairman of the Board and Chief Executive Officer Dr. Maky Za...

2023-11-07 07:14:34 ET More on Summit Therapeutics Summit Therapeutics: Not For Retail Investors Navigating Summit Therapeutics' Bispecific Bet Amid Cash Constraints Summit Therapeutics, Inc. (SMMT) Q2 2023 Earnings Call Transcript Financial information for S...

Enrollment Initiated in Second Phase III Clinical Study for Ivonescimab, HARMONi-3 Continuing Enrollment of HARMONi Phase III Study, with Enrollment Completion Expected in Second Half of 2024 Manmeet S. Soni Joined Summit as COO, Invested $5 Million in the Company Dave Gan...